Tepper received the Hart-Scott-Rodino anti-trust clearances on
Wednesday, according to the FTC's website.
Wells Fargo analyst David Maris said in a research note that
Allergan "indicated this clearance provides flexibility to the filer
as to whether they want take an activist approach to the investment
or not."
Tepper's Appaloosa LP increased its stake in Allergan to 3.7 million
shares from around 3.5 million shares over the last quarter, the
firm said in a filing with the Securities and Exchange Commission on
Tuesday.
"Allergan welcomes all investments in our company," spokeswoman Amy
Rose said, when asked about the clearances. Appaloosa was not
immediately available for comment.
[to top of second column] |
The company's shares roe $5.70, or 3.7 percent, to $160.23 on
Thursday.
Botox maker Allergan launched a strategic review of its business
earlier this year. CEO Brent Saunders said in March the declining
stock price required the company to look at all options "with a
sense of urgency."
Still, Saunders indicated on the company's earnings conference call
last month that he did not feel a fundamental change to the
company's strategy was necessary.
(Reporting by Michael Erman; Editing by Cynthia Osterman)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |